PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that Tim M. Mayleben, Esperion's president and
chief executive officer, will present at the Credit Suisse Healthcare
Conference in Scottsdale, Ariz. The presentation will take place on
Tuesday, November 12, at 8 a.m. MST/11:00 a.m. EST.
To hear the live audio webcast and view the slides of the Esperion
presentation, please visit http://cc.talkpoint.com/cred001/111313a_jw/?entity=52_JLBR8CO.
A replay of the webcast will be available on the company's website for
90 days following the live event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on
the research, development and commercialization of therapies for the
treatment of patients with elevated levels of low-density lipoprotein
cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower levels of LDL-C
and to avoid side effects associated with existing LDL-C lowering
therapies. ETC-1002 is targeted for statin intolerant patients with
elevated levels of LDL-C. Esperion has completed seven clinical studies
to date, including four Phase 2a studies, and has initiated a robust
Phase 2b clinical program. For more information, please visit www.esperion.com.
BrewLife
Denise Powell, 510-703-9491
dpowell@brewlife.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media